NCT06007846

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Inova Health Care Services · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.

Conditions

• Hepatocellular Carcinoma
• Cirrhosis

Interventions

Type	Name	Description
DRUG	Namenda	Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily

Timeline

• Start date: 2023-07-31
• Primary completion: 2026-07-31
• Completion: 2026-08-31
• First posted: 2023-08-23
• Last updated: 2025-09-30

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study